Literature DB >> 11986938

Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes.

S Tauro1, M D Hepburn, C M Peddie, D T Bowen, M J Pippard.   

Abstract

The potential contribution of abnormal marrow stromal function to ineffective haemopoiesis in the myelodysplastic syndromes is unclear. We have compared the ability of stromal layers from normal (n = 7) and myelodysplastic (n = 9) marrow to alter proliferation and survival of the granulocyte-macrophage colony-stimulating factor/interleukin-3-dependent cell line F-36P. Co-cultures for 72 h in the absence of exogenous cytokines were either in direct contact with stroma or separated by transwell inserts. On normal stromal layers, the ratio of adherent F-36P cells relative to stromal cells increased from a mean of 0.2 +/- 0.01 (s.d.) at 4 h of co-culture to 0.34 +/- 0.08 after 72 h (n = 7). Corresponding values on myelodysplastic stroma (0.2 +/- 0.02 at 4 h and 0.35 +/- 0.05 at 72 h; n = 9) indicated that the ability of myelodysplastic stromal layers to regulate short-term proliferation of F-36P cells may be similar to normal. Apoptosis of F-36P cells was quantified after co-culture with normal or myelodysplastic stroma: results from myelodysplastic co-cultures were standardized as a fraction of values from co-cultures with paired normal stroma (apoptotic ratio). Augmented apoptosis of F-36P cells was detected in 8/9 co-cultures with myelodysplastic stroma (mean = 15.7 +/- 9.7%, n = 9), compared with corresponding normal stroma (mean = 12.4 +/- 4.6%, n = 7, P < 0.05) with a mean apoptotic ratio of 1.4 +/- 0.5 (P < 0.05). There was no correlation between stroma-related apoptosis and FAB type, tumour necrosis factor-alpha concentrations in the culture supernatant or numbers of stromal macrophages, and no evidence of involvement of the Fas pathway. Increased apoptosis was detected in cells grown in transwell inserts over stroma (23.8 +/- 3%, n = 5) compared to adherent cells in cultures with normal stromal layers, but this survival difference was not observed in co-cultures with myelodysplastic stroma. These results suggest that abnormal stromal function in patients with myelodysplastic syndromes may contribute to increased apoptosis of haemopoietic cells within the marrow microenvironment. The effect appears to be dependent on close cellular contact, rather than the release of soluble factors, but the exact mechanism remains unclear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986938     DOI: 10.1038/sj.leu.2402440

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Authors:  Carmen Mariana Aanei; Pascale Flandrin; Florin Zugun Eloae; Eugen Carasevici; Denis Guyotat; Eric Wattel; Lydia Campos
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

Review 2.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.

Authors:  Chengming Fei; Youshan Zhao; Shucheng Gu; Juan Guo; Xi Zhang; Xiao Li; Chunkang Chang
Journal:  Tumour Biol       Date:  2014-01-19

4.  Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence.

Authors:  Qinghua Liu; Hongbo Zhu; Jing Dong; Helou Li; Hong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.

Authors:  Diana Campioni; Paola Secchiero; Federica Corallini; Elisabetta Melloni; Silvano Capitani; Francesco Lanza; Giorgio Zauli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.

Authors:  Gergely Varga; Judit Kiss; Judit Várkonyi; Virág Vas; Péter Farkas; Katalin Pálóczi; Ferenc Uher
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

7.  Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes.

Authors:  A Poloni; G Maurizi; D Mattiucci; S Amatori; B Fogliardi; B Costantini; M Mariani; S Mancini; A Olivieri; M Fanelli; P Leoni
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

8.  Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.

Authors:  Miyoung Kim; Seungwoo Hwang; Kiejung Park; Seon Young Kim; Young Kyung Lee; Dong Soon Lee
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

9.  The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes.

Authors:  Zhenling Wang; Xiaoqiong Tang; Wen Xu; Zeng Cao; Li Sun; Weiming Li; Qiubai Li; Ping Zou; Zhigang Zhao
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia.

Authors:  M J Groves; C E Johnson; J James; A R Prescott; J Cunningham; S Haydock; C Pepper; C Fegan; L Pirrie; N J Westwood; P J Coates; I G Ganley; S Tauro
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.